Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases... Show more
a company that discovers and develops novel, small molecule pharmaceuticals
Industry Biotechnology
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with EDIT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +0.17% | ||
| EDIT - VRTX | 43% Loosely correlated | +1.89% | ||
| RPRX - VRTX | 42% Loosely correlated | -0.24% | ||
| BMRN - VRTX | 42% Loosely correlated | +0.26% | ||
| ACAD - VRTX | 40% Loosely correlated | +0.32% | ||
| INCY - VRTX | 40% Loosely correlated | -1.47% | ||
More | ||||
Be on the lookout for a price bounce soon.
Following a +1.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 237 of 363 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 186 of 285 cases where VRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
The 10-day RSI Indicator for VRTX moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 22 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRTX as a result. In 41 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
The Moving Average Convergence Divergence Histogram (MACD) for VRTX turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 29 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 41%.
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.452) is normal, around the industry mean (19.963). P/E Ratio (30.020) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (1.894) is also within normal values, averaging (2.528). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (10.493) is also within normal values, averaging (427.708).